MGF Farmácia Magistral v. AstraZeneca: SGLT2 Patent Appeal Dismissed in Brazil
Brazilian compounding pharmacy MGF Farmácia Magistral sought to overturn an unfavourable declaratory judgement ruling against AstraZeneca’s SGLT2 inhibitor patent BRPI0311323B1. The Court of Justice of São Paulo dismissed the appeal on 27 November 2024, finding the motion for clarification was used impermissibly to relitigate the merits.
Compounding pharmacy’s declaratory challenge to AstraZeneca’s SGLT2 patent fails at appeal
MGF Farmácia Magistral Ltda, a Brazilian compounding pharmacy, initiated declaratory judgement proceedings against AstraZeneca AB in the São Paulo state courts, targeting Brazilian patent BRPI0311323B1. That patent protects a C-aryl glucoside SGLT2 inhibitor compound — the pharmacological class underlying blockbuster diabetes medicines including dapagliflozin. The case was filed under case number 1102084-87.2022.8.26.0100/50000 and adjudicated within the Court of Justice of São Paulo.
The appeal was dismissed on 27 November 2024. The court found that the appellants had attempted to use a motion for clarification (embargos de declaração) as a vehicle to reverse an unfavourable first-instance decision on the merits — a procedurally impermissible purpose under Brazilian civil procedure. Because the motion did not identify any genuine ambiguity, obscurity, or contradiction in the lower ruling, the court rejected it outright, leaving the original decision adverse to MGF intact.
The dismissal on procedural grounds means the substantive validity and enforceability of BRPI0311323B1 were not re-examined at this appellate stage. The public record does not disclose the precise first-instance outcome, the specific invalidity or non-infringement arguments MGF advanced, or whether further appeal routes were pursued. The result is nonetheless consistent with AstraZeneca’s established global strategy of defending its SGLT2 inhibitor patent estate against generic and compounding-sector challengers.
Filing to Appeal Dismissed in 0 days
Case closed 27 November 2024; filing date not on public record
Appeal dismissed: what the São Paulo court’s ruling means for both parties
Impermissible use of clarification motion ends the appeal
Under Brazilian civil procedure, embargos de declaração (motions for clarification) are a narrow remedy designed to cure ambiguity, obscurity, contradiction, or omission in a judicial decision. They cannot be used to relitigate the merits or reverse an unfavourable outcome. The court found MGF’s motion did exactly that, making dismissal the mandatory procedural consequence — no merits review was triggered.
Procedural dismissal — no merits rulingMGF’s declaratory challenge leaves AstraZeneca’s patent standing
The dismissal means the first-instance decision adverse to MGF remains in force. MGF did not secure a declaratory ruling of invalidity or non-infringement. The public record does not specify whether further ordinary appeal routes remain available to MGF, but having failed to correct procedural form at this stage, its litigation position is materially weakened. Compounding pharmacies seeking to commercialise SGLT2 inhibitor formulations in Brazil face continued patent risk.
Challenger position weakenedAstraZeneca’s SGLT2 patent survives this appellate challenge
BRPI0311323B1 emerges from this proceeding with its enforceability intact in Brazil. The court’s procedural dismissal effectively preserved the first-instance outcome in AstraZeneca’s favour without requiring any fresh substantive defence of the patent’s validity. This outcome is consistent with AstraZeneca’s broader effort to maintain exclusivity over its SGLT2 inhibitor portfolio in emerging markets as dapagliflozin faces growing generic pressure.
Patent enforceability maintainedSGLT2 compounding market in Brazil faces continued patent barrier
The failed challenge suggests that state-court declaratory routes targeting BRPI0311323B1 carry meaningful procedural risk, particularly where the challenging party cannot satisfy the strict formal requirements of Brazilian appellate procedure. For compounding pharmacies and generic manufacturers monitoring SGLT2 inhibitor freedom-to-operate in Brazil, this dismissal reinforces that patent challenges must be structured with precision from the first instance — procedural missteps are unlikely to be cured on appeal.
Higher bar for SGLT2 challengers in BrazilFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | MGF FARMÁCIA MAGISTRAL LTDA | Individual | Brazilian compounding pharmacy — challenger of BRPI0311323B1 SGLT2 inhibitor patentSearch in Eureka ↗ |
| Defendant | AstraZeneca AB | Individual | AstraZeneca AB — originator holder of SGLT2 inhibitor patent BRPI0311323B1Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The court’s ruling is unambiguously procedural: the appellants used a motion for clarification to attempt a merits reversal, which Brazilian civil procedure expressly prohibits. The verdict language — ‘the motion for clarification… are rejected’ — confirms the court declined to engage with the substance of the patent dispute. For AstraZeneca, this is an unqualified procedural win; BRPI0311323B1’s validity was neither examined nor disturbed. For MGF, no merits adjudication was obtained, leaving the original adverse first-instance decision fully operative.
BRPI0311323B1 — C-aryl glucoside SGLT2 inhibitor compound and pharmaceutical composition
BRPI0311323B1 is a Brazilian granted patent protecting a C-aryl glucoside compound that functions as a sodium-glucose co-transporter 2 (SGLT2) inhibitor, together with pharmaceutical compositions incorporating that compound. SGLT2 inhibitors reduce blood glucose by blocking glucose reabsorption in the kidney, and the C-aryl glucoside structural class is the pharmacophore underlying dapagliflozin (Farxiga/Forxiga), one of AstraZeneca’s highest-revenue diabetes products globally. The patent originates from an international application filed in 2003, with Brazilian national phase designation.
For the Brazilian pharmaceutical market, BRPI0311323B1 represents a key exclusivity barrier in the SGLT2 inhibitor segment — a class that has expanded beyond diabetes into heart failure and chronic kidney disease. AstraZeneca has actively defended equivalent patents in multiple jurisdictions worldwide. Any company seeking to manufacture, compound, or commercialise dapagliflozin or structurally similar SGLT2 inhibitor formulations in Brazil faces direct exposure to this patent until expiry, making freedom-to-operate analysis against the full claim scope essential before market entry.
Should you run an FTO analysis against BRPI0311323B1?
Any company developing, compounding, or distributing SGLT2 inhibitor-based pharmaceutical products in Brazil — including dapagliflozin formulations, SGLT2/DPP-4 combination therapies, or structurally related C-aryl glucoside compounds — should conduct a current freedom-to-operate assessment against BRPI0311323B1. This case confirms the patent remains enforced and that state-court challenges have not neutralised it. Generic manufacturers, contract development organisations, and compounding pharmacies are the highest-risk categories.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map claim scope against product structures, identify design-around opportunities, and benchmark against AstraZeneca’s broader SGLT2 patent family in Brazil and internationally. Eureka can also model patent expiry timelines and flag any supplementary protection or pipeline patent filings that may extend the effective exclusivity period beyond the primary patent term.
Run a freedom-to-operate analysis on BRPI0311323B1 to assess your product’s exposure
Run FTO in Eureka →Similar SGLT2 inhibitor patent cases in Brazilian and Latin American courts
Explore related SGLT2 inhibitor patent disputes and AstraZeneca declaratory judgement proceedings filed in Brazilian courts and comparable jurisdictions.
What this case signals for the SGLT2 inhibitor IP landscape in Brazil
A procedural dismissal carries real strategic weight — it leaves AstraZeneca’s core SGLT2 patent intact and raises the bar for future challengers.
Procedural form is decisive in Brazilian patent declaratory actions
This case illustrates that substantive patent arguments will not be heard if the appellate vehicle is procedurally defective. Parties challenging pharmaceutical patents in Brazilian state courts must structure their appeals under the correct procedural mechanism from the outset. A misfiled clarification motion cannot substitute for an ordinary appeal and will be dismissed without merits review.
AstraZeneca’s SGLT2 patent estate remains a live enforcement risk in Brazil
BRPI0311323B1 survived this challenge with enforceability unaffected. For any company — compounding pharmacy, generic manufacturer, or biosimilar developer — contemplating SGLT2 inhibitor formulations in the Brazilian market, a current freedom-to-operate analysis against this patent and related AstraZeneca filings is strongly advisable before product launch or scale-up.
LTDA v AstraZeneca — key questions answered
The Court of Justice of São Paulo dismissed the appeal on 27 November 2024. MGF Farmácia Magistral had attempted to use a motion for clarification to reverse an unfavourable first-instance declaratory judgement ruling, but the court found this procedurally impermissible. AstraZeneca’s patent BRPI0311323B1 was not substantively reviewed and remains in force.
BRPI0311323B1 is a Brazilian patent covering a C-aryl glucoside SGLT2 inhibitor compound and pharmaceutical compositions. This structural class underlies dapagliflozin (Farxiga), AstraZeneca’s major diabetes and heart failure drug. The patent is a central exclusivity asset for AstraZeneca in Brazil, blocking generic and compounding commercialisation of SGLT2 inhibitor formulations within its claim scope.
Embargos de declaração is a narrow procedural motion under Brazilian civil procedure used to cure specific defects — ambiguity, obscurity, contradiction, or omission — in a judicial decision. It is not an appeal on the merits. In this case, the court found MGF used it to attempt a merits reversal, which is impermissible, resulting in outright rejection without any substantive review of the patent dispute.
The dismissal preserves the first-instance outcome in AstraZeneca’s favour and leaves BRPI0311323B1 enforceable, but it does not constitute a judicial finding of validity — no merits analysis was conducted at the appellate stage. The patent’s validity could potentially still be challenged through other procedural routes, including INPI administrative nullity proceedings, subject to applicable time limits.
Compounding pharmacies seeking to prepare or dispense SGLT2 inhibitor formulations — particularly dapagliflozin or structurally similar C-aryl glucoside compounds — in Brazil face direct patent risk from BRPI0311323B1. This case’s outcome confirms the patent is actively enforced and has survived a state-court challenge. A freedom-to-operate analysis covering claim scope, patent term, and any related AstraZeneca filings is advisable before compounding activity is commenced or expanded.
PatSnap Eureka searches patents and litigation data to answer instantly.